/PBIGF
PBIGF Stock - Paradigm Biopharmaceuticals Limited
Healthcare|BiotechnologyOTC
$0.23+0.00%
+$0.00 (+0.00%) • Dec 19
62
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.28
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.25
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for PBIGF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.22 – $0.23
TARGET (TP)$0.26
STOP LOSS$0.21
RISK/REWARD1:2.3
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.28
52W High$0.38
52W Low$0.13
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $52,120 | $65,800 | N/A | $79,224 | $20,550 |
| Gross Profit | $-19,892 | $56,812 | $27,933 | $-64,527 | $-78,588 |
| Gross Margin | -38.2% | 86.3% | N/A | -81.4% | -382.4% |
| Operating Income | $-22,886,205 | $-65,193,000 | $-60,085,267 | $-47,929,557 | $-43,180,558 |
| Net Income | $-18,770,745 | $-58,653,000 | $-51,910,000 | $-39,250,000 | $-34,297,000 |
| Net Margin | -36014.5% | -89138.3% | N/A | -49543.1% | -166895.4% |
| EPS | $-0.06 | $-0.20 | $-0.18 | $-0.16 | $-0.16 |
Company Overview
Paradigm Biopharmaceuticals Limited, a drug repurposing company, engages in the research and development of therapeutic products for human use in Australia. It offers pentosan polysulfate sodium drugs in the injectable form for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is based in Melbourne, Australia.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
PBIGFBeat Rate
0%
Last 0 quarters
Avg Surprise
+0%
EPS vs Estimate
Beats / Misses
0/0
Last 12 quarters
Latest EPS
$-0.01
Q1 2025
EPS Surprise History
Q1 23
No data
Q2 23
No data
Q1 24
No data
Q1 24
No data
Q2 24
No data
Q3 24
No data
Q4 24
No data
Q1 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Feb 26, 2026 | — | — | — | — |
Q2 2025 | Apr 29, 2025 | — | — | — | — |
Q1 2025 | Feb 26, 2025 | — | $-0.01 | — | — |
Q4 2024 | Oct 30, 2024 | — | $-0.01 | — | — |
Q3 2024 | Aug 30, 2024 | — | $-0.01 | — | — |
Q2 2024 | Apr 29, 2024 | — | $-0.01 | — | — |
Q1 2024 | Mar 21, 2024 | — | $-0.11 | — | — |
Q1 2024 | Jan 30, 2024 | — | $-0.05 | — | — |
Q2 2023 | Jun 30, 2023 | — | $-0.02 | — | — |
Q1 2023 | Mar 31, 2023 | — | $-0.02 | — | — |
Q1 2023 | Feb 26, 2023 | — | $-0.04 | — | — |
Q4 2022 | Dec 31, 2022 | — | $-0.04 | — | — |
Q3 2022 | Aug 25, 2022 | — | $-0.02 | — | — |
Q2 2022 | Jun 30, 2022 | — | $-0.04 | — | — |
Q1 2022 | Feb 23, 2022 | — | $-0.04 | — | — |
Q4 2021 | Dec 31, 2021 | — | $-0.08 | — | — |
Q3 2021 | Aug 26, 2021 | — | $-0.02 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-0.04 | — | — |
Q1 2021 | Feb 23, 2021 | — | $-0.03 | — | — |
Q4 2020 | Dec 31, 2020 | — | $-0.07 | — | — |
Latest News
Loading news...
Frequently Asked Questions about PBIGF
What is PBIGF's current stock price?
Paradigm Biopharmaceuticals Limited (PBIGF) is currently trading at $0.23 per share. The stock has moved +0.00% today.
What is the analyst price target for PBIGF?
No analyst price targets are currently available for this stock.
What sector is Paradigm Biopharmaceuticals Limited in?
Paradigm Biopharmaceuticals Limited operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the OTC exchange.
What is PBIGF's market cap?
Paradigm Biopharmaceuticals Limited has a market capitalization of $0.09 billion, making it a small-cap company.
Does PBIGF pay dividends?
No, Paradigm Biopharmaceuticals Limited does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAURX
Nuo Therapeutics, Inc.
$2.15
Mkt Cap: $0.1B
IUGNF
Imugene Limited
$0.22
Mkt Cap: $0.1B
KNTPF
Kintor Pharmaceutical Limited
$0.22
Mkt Cap: $0.1B
MSCLF
Satellos Bioscience Inc.
$0.48
Mkt Cap: $0.1B
ORXOF
Orexo AB (publ)
$3.05
Mkt Cap: $0.1B
PFGTF
Pacific Edge Limited
$0.10
Mkt Cap: $0.1B
POLBF
Poolbeg Pharma PLC
$0.04
Mkt Cap: $0.0B
SHIEF
Shield Therapeutics plc
$0.09
Mkt Cap: $0.1B
SPHRY
Starpharma Holdings Limited
$2.20
Mkt Cap: $0.1B
VSBC
VitaSpring Biomedical Co. Ltd.
$1.00
Mkt Cap: $0.2B
Explore stocks similar to PBIGF for comparison